▲ S&P 500 +---%|▲ Stock Advisor +---%Join The Motley Fool

AccessibilityHelp

Leo Sun

TMFSunLion

Leo Sun is a contributing Motley Fool stock market analyst who has worked with the company since 2013, covering technology, consumer goods, industrial, and financial sectors. He became a self-made millionaire by age 40 through long-term investing, crediting lessons from Warren Buffett and Peter Lynch. Leo is a regular guest on CNBC Asia providing stock analysis on Chinese technology companies, including Tencent, Baidu, and Alibaba. He previously wrote for InvestorGuide and holds a bachelor’s degree in English from the University of Texas at Austin.

Articles by Leo Sun — Page 465

The Hunger Games: Mockingjay -- Are Two Movies Too Many?

Jan 25, 2014 by Leo Sun

The Hunger Games: Mockingjay -- Are Two Movies Too Many?

Lionsgate has just released the poster for Mockingjay, the third chapter of The Hunger Games. The film will be split into two parts, continuing Hollywood’s new tradition of splitting short books into long films. Will this strategy be a bane or boon for Mockingjay?

Will Agent Carter Be More Marvelous Than Marvel’s Agents of SHIELD?

Jan 24, 2014 by Leo Sun

Will Agent Carter Be More Marvelous Than Marvel’s Agents of SHIELD?

Disney recently announced the development of a new series, Agent Carter, as the next Marvel TV spin-off following the release of Marvel’s Agents of SHIELD last fall. Will it fare better or worse than its predecessor?

3 Things You Must Know About E-Cigarettes

Jan 23, 2014 by Leo Sun

3 Things You Must Know About E-Cigarettes

Altria, Philip Morris International, Reynolds American, and Lorillard have all recently entered the e-cigarettes market. What are 3 key things consumers need to know about these products, which companies claim are much safer than traditional cigarettes?

LogMeIn Discontinues Free Service, Leaving Customers Hanging Out to Dry: 3 Lessons Learned

Jan 23, 2014 by Leo Sun

LogMeIn Discontinues Free Service, Leaving Customers Hanging Out to Dry: 3 Lessons Learned

LogMeIn just abruptly discontinued its free service, prompting an outcry from its users. What 3 key lessons can we learn from LogMeIn logging its free users out?

3 Things To Know About Opko Health

Jan 23, 2014 by Leo Sun

3 Things To Know About Opko Health

Opko Health has had a volatile but profitable ride over the past 12 months. Here are three key aspects of the company to consider -- which also involve its industry peers Teva, Amgen, Roche, and Tesaro.

mappagigante

Jan 22, 2014 by Leo Sun

Can Elder Scrolls Online Generate an MMO Following From a Single-Player Fan Base?

Can Bethesda's Elder Scrolls Online successfully turn a traditionally single-player affair into a multiplayer one?

Why You Need to Watch Teva, AMAG, AstraZeneca, and Nektar Therapeutics This Morning

Jan 22, 2014 by Leo Sun

Why You Need to Watch Teva, AMAG, AstraZeneca, and Nektar Therapeutics This Morning

Teva Pharmaceutical, AMAG Pharmaceuticals, AstraZeneca, and Nektar Therapeutics could loom large in health-care headlines this morning. Here’s why.

650x428xplus1.png.pagespeed.ic.3GJxD_JjCa

Jan 21, 2014 by Leo Sun

Plus-Size Mistakes by H&M, Mango, and Target Spark Fierce Fashion Debates

H&M, Mango, and Target all made serious blunders in advertising their plus-size clothing lines. Are angry customers overreacting to their mistakes?

Why Did This Generics Maker Just Divest its Chinese and European Operations?

Jan 21, 2014 by Leo Sun

Why Did This Generics Maker Just Divest its Chinese and European Operations?

Generics giant Actavis recently exited the Chinese market and divested a large part of its European operations. What prompted such a dramatic move, and how could it affect Actavis’ industry peers Teva, Mylan, Valeant, and Novartis?

Acetaminophen: 4 Things to Know About This Common Over-the-Counter Drug

Jan 21, 2014 by Leo Sun

Acetaminophen: 4 Things to Know About This Common Over-the-Counter Drug

The FDA recently issued a warning regarding liver damage caused by acetaminophen. Here are four things consumers and investors need to know about the drug, and how it could affect companies like Johnson & Johnson, Novartis, GlaxoSmithKline, and Zogenix.

Why Amarin Corporation, CytRx Corporation, and Aegerion Pharmaceuticals Could Be the Biggest Biotech Stories of the Day

Jan 21, 2014 by Leo Sun

Why Amarin Corporation, CytRx Corporation, and Aegerion Pharmaceuticals Could Be the Biggest Biotech Stories of the Day

Amarin, CytRx, and Aegerion could all make health care headlines this morning. Here's why.

3 Reasons Nintendo's Wii U Failed

Jan 20, 2014 by Leo Sun

3 Reasons Nintendo's Wii U Failed

Nintendo expects a 70% drop in Wii U sales for fiscal 2013. Let’s take a look at 3 big reasons that the underdog eighth-generation console failed.

Ariad Pharmaceuticals, Inc. and Amarin Corporation plc (ADR): Can These Biotechs Bounce Back in 2014?

Jan 18, 2014 by Leo Sun

Ariad Pharmaceuticals, Inc. and Amarin Corporation plc (ADR): Can These Biotechs Bounce Back in 2014?

Ariad and Amarin were crushed near the end of 2013. Can these two broken biotech stocks make a comeback in 2014, and how will their ultimate fates affect pharmaceutical giants Novartis and GlaxoSmithKline?

3 Reasons Regeneron Can Keep Rising in 2014

Jan 17, 2014 by Leo Sun

3 Reasons Regeneron Can Keep Rising in 2014

Regeneron has had a great run over the past 12 months. Will these 3 bullish indicators -- which also affect Bayer, Novartis, Roche, and Sanofi -- catapult the stock to new heights in 2014?

captain-phillips-wasnt-the-first-time-tom-hanks-had-a-role-in-a-thriller

Jan 17, 2014 by Leo Sun

Oscar Nominations of 2014: The Year of the Contemporary Historical Drama

The Oscar nominations are in -- and 5 of the 9 films nominated for Best Picture were historical dramas. Is this the start of a new trend in American cinema, and could it be dangerous for filmmakers to blur the lines between fact and fiction?

3 Reasons Exelixis, Inc. Could Excel in 2014

Jan 16, 2014 by Leo Sun

3 Reasons Exelixis, Inc. Could Excel in 2014

Exelixis has rallied strongly over the past 12 months, despite only having a single approved drug, which is only expected to generate $50 million in peak revenues. Can the stock continue soaring thanks to these 3 catalysts, and how does its future involve AstraZeneca, Johnson & Johnson, Medivation, and Roche?

Can Gotham and Constantine TV Shows Succeed Where Marvel’s Agents of SHIELD Failed?

Jan 16, 2014 by Leo Sun

Can Gotham and Constantine TV Shows Succeed Where Marvel’s Agents of SHIELD Failed?

Two new DC comic properties, Gotham and Constantine, are headed to the small screen. Can they succeed where Marvel’s Agents of SHIELD failed?

Net Neutrality Rules Get Nixed: Key Facts and Opinions to Consider

Jan 16, 2014 by Leo Sun

Net Neutrality Rules Get Nixed: Key Facts and Opinions to Consider

The FCC’s net neutrality rules just got nixed by the federal court, clearing the way for ISPs to offer tiered bandwidth-based pricing schemes. Will customers ultimately benefit or suffer from this radical change?

3 Ways Johnson & Johnson Is Revolutionizing Diabetes Care

Jan 15, 2014 by Leo Sun

3 Ways Johnson & Johnson Is Revolutionizing Diabetes Care

Johnson & Johnson rarely gets much attention for its efforts in diabetes treatments. Let’s take a look at three of the company’s interesting new efforts to treat diabetes, and how they could affect companies like AstraZeneca, Bristol-Myers Squibb, Medtronic, DexCom, and Sanofi.

Will Conservative Guidance Sink This Big Biotech in 2014?

Jan 15, 2014 by Leo Sun

Will Conservative Guidance Sink This Big Biotech in 2014?

Celgene recently slipped on weaker-than-expected guidance for 2014. Should investors buy the dip? Let’s compare Celgene to its big biotech peers Amgen, Biogen, and Gilead Sciences, to better understand its business and growth catalysts.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services